ArticleFrontiers in nuclear medicine2025
Prevalence and clinical significance of unsuspected intracranial findings in patients undergoing oncological whole-body 18F-FDG PET/CT imaging.
Article in Frontiers in nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Routine oncological whole-body 18F-1-fluoro-2-deoxyglucose (FDG) PET/CT in the majority of institutions is performed from the base of the skull to the mid-thigh. However, at our institution, the brain is included. The aim of this study was to identify the prevalence of unsuspected intracranial findings in patients undergoing oncological 18F-FDG PET/CT examinations with inclusion of the brain in the field of view. Methods: A total of 3,523 patients who underwent oncological limited whole-body 18F-FDG PET/CT scans between February 2019 and December 2021 were retrospectively reviewed. The study variables included the patient's age, sex, type of malignancy, disease stage, and clinical presentation and the presence of clinically unsuspected intracranial findings. The intracranial findings were correlated with brain MRI findings in a subset of patients. Clinical significance, defined by a change in disease stage and/or patient management informed by the identification of unsuspected intracranial findings, was assessed. Results: In total, 132/3,523 (3.7%) oncological whole-body 18F-FDG PET/CT scans had unsuspected intracranial findings, of which clinically significant unsuspected intracranial findings were found in 62 cases (1.4%). The most common intracranial findings were metastasis, followed by subclinical vascular findings. Moreover, 22/62 cases underwent follow-up brain MRI, and the sensitivity and specificity of the 18F-FDG PET/CT scans were 94.7% and 66.7%, respectively. Data on post-PET/CT management were available for 32/132 patients. A change in management was observed in 25/32 (78%) cases. Conclusion: The inclusion of the brain in the field of view in oncological whole-body 18F-FDG PET/CT may lead to the early detection of unsuspected intracranial metastases and changes in patient management. This is especially true for breast and lung cancers, which have a greater propensity to metastasize to the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.